Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in three major investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference (09/05), the Morgan Stanley Global Healthcare Conference (09/08), and the H.C. Wainwright Global Investment Conference (09/09). CEO Mark Erlander will present a fireside chat at the H.C. Wainwright conference at 10:30 AM ET, which will be available via webcast on the company's website.
Cardiff Oncology (Nasdaq: CRDF), società biotech in fase clinica specializzata nell'inibizione di PLK1 per terapie oncologiche, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a settembre 2025.
L'azienda sarà presente al Wells Fargo Healthcare Conference (05/09), al Morgan Stanley Global Healthcare Conference (08/09) e all'H.C. Wainwright Global Investment Conference (09/09). Il CEO Mark Erlander parteciperà a un fireside chat alla conferenza H.C. Wainwright alle 10:30 AM ET; la sessione sarà trasmessa in webcast sul sito web della società.
Cardiff Oncology (Nasdaq: CRDF), una compañía biofarmacéutica en etapa clínica centrada en la inhibición de PLK1 para terapias contra el cáncer, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La compañía asistirá al Wells Fargo Healthcare Conference (05/09), al Morgan Stanley Global Healthcare Conference (08/09) y al H.C. Wainwright Global Investment Conference (09/09). El CEO Mark Erlander participará en una charla informal (fireside chat) en la conferencia de H.C. Wainwright a las 10:30 AM ET; la presentación estará disponible por webcast en la página web de la compañía.
Cardiff Oncology (Nasdaq: CRDF))는 암 치료를 위한 PLK1 억제에 중점을 둔 임상 단계의 바이오텍 회사로, 2025년 9월에 열리는 세 곳의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 Wells Fargo Healthcare Conference(09/05), Morgan Stanley Global Healthcare Conference(09/08), H.C. Wainwright Global Investment Conference(09/09)에 참석할 예정입니다. CEO 마크 얼랜더(Mark Erlander)는 H.C. Wainwright 컨퍼런스에서 동 포럼 스타일의 대화(fireside chat)에 참여하며, 이는 동사 웹사이트를 통해 웹캐스트로 시청할 수 있습니다. 발표 시간은 동부 표준시 기준 오전 10시 30분(10:30 AM ET)입니다.
Cardiff Oncology (Nasdaq: CRDF), une société biotechnologique en phase clinique spécialisée dans l'inhibition de PLK1 pour des thérapies anticancer, a annoncé sa participation à trois grandes conférences pour investisseurs en septembre 2025.
La société assistera à la Wells Fargo Healthcare Conference (05/09), à la Morgan Stanley Global Healthcare Conference (08/09) et à la H.C. Wainwright Global Investment Conference (09/09). Le PDG Mark Erlander animera un fireside chat lors de la conférence H.C. Wainwright à 10h30 (ET); la session sera disponible en webcast sur le site web de l'entreprise.
Cardiff Oncology (Nasdaq: CRDF), ein klinisch tätiges Biotech-Unternehmen mit Fokus auf PLK1-Hemmung für Krebstherapien, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Wells Fargo Healthcare Conference (05.09.), der Morgan Stanley Global Healthcare Conference (08.09.) und der H.C. Wainwright Global Investment Conference (09.09.) teilnehmen. CEO Mark Erlander wird auf der H.C. Wainwright-Konferenz an einem Fireside-Chat um 10:30 AM ET teilnehmen; dieser wird per Webcast auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025.
Details of the events can be found below.
Wells Fargo 20th Annual Healthcare Conference
Format: 1x1 Meetings
Date: 09/05/2025
Location: Encore Boston Harbor, Everett, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: 09/08/2025
Location: Sheraton New York Times Square, New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat and 1x1 Meetings
Presenter: Mark Erlander, CEO
Date: 09/09/2025
Time: 10:30 AM ET
Location: Lotte New York Palace Hotel, New York, NY
Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Meghan Bianco
Taft Communications, a division of RF|Binder
609-544-5446
meghan.bianco@rfbinder.com
FAQ
When is Cardiff Oncology (CRDF) presenting at the H.C. Wainwright conference?
Which investor conferences is Cardiff Oncology (CRDF) attending in September 2025?
How can investors access Cardiff Oncology's (CRDF) H.C. Wainwright conference presentation?
What is Cardiff Oncology's (CRDF) main focus as a company?
